Lb Pharmaceuticals (LBRX) Assets Average (2025 - 2026)
Lb Pharmaceuticals' quarterly Assets Average came in at $353.2 million in Q1 2026, up 11.48% quarter-over-quarter from $316.8 million in Q4 2025.
Lb Pharmaceuticals has reported Assets Average for 2 years, with the latest figure at $353.2 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average changed N/A year-over-year to $353.2 million; the trailing twelve-month figure through Mar 2026 stood at $353.2 million (changed N/A YoY), and the FY2025 full-year result was $173.2 million, changed N/A from the prior year.
- Assets Average for Q1 2026 stood at $353.2 million, up from $316.8 million in the prior quarter.
- The five-year high for Assets Average was $353.2 million in Q1 2026, with the low at $316.8 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - | 353.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353.21 Mn |
| Dec 31, 2025 | 316.84 Mn |